Correction to: Trastuzumab Emtansine: A Review of Its Adjuvant Use in Residual Invasive HER2-Positive Early Breast Cancer

被引：0
|
作者：
Katherine A. Lyseng-Williamson
机构：
[1] Springer Nature,
来源：
Drugs | 2020年 / 80卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The author has alerted us to the following error.
引用
收藏
页码：2001 / 2001
相关论文
共 50 条
  • [1] Trastuzumab Emtansine: A Review of Its Adjuvant Use in Residual Invasive HER2-Positive Early Breast Cancer
    Katherine A. Lyseng-Williamson
    Drugs, 2020, 80 : 1723 - 1730
  • [2] Trastuzumab Emtansine: A Review of Its Adjuvant Use in Residual Invasive HER2-Positive Early Breast Cancer
    Lyseng-Williamson, Katherine A.
    DRUGS, 2020, 80 (16) : 1723 - 1730
  • [3] Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
    von Minckwitz, G.
    Huang, C. -S.
    Mano, M. S.
    Loibl, S.
    Mamounas, E. P.
    Untch, M.
    Wolmark, N.
    Rastogi, P.
    Schneeweiss, A.
    Redondo, A.
    Fischer, H. H.
    Jacot, W.
    Conlin, A. K.
    Arce-Salinas, C.
    Wapnir, I. L.
    Jackisch, C.
    DiGiovanna, M. P.
    Fasching, P. A.
    Crown, J. P.
    Wuelfing, P.
    Shao, Z.
    Caremoli, E. Rota
    Wu, H.
    Lam, L. H.
    Tesarowski, D.
    Smitt, M.
    Douthwaite, H.
    Singel, S. M.
    Geyer, C. E., Jr.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (07): : 617 - 628
  • [4] Trastuzumab Emtansine: A Review of Its Adjuvant Use in Residual Invasive HER2-Positive Early Breast Cancer (vol 80, pg 1723, 2020)
    Lyseng-Williamson, Katherine A.
    DRUGS, 2020, 80 (18) : 2001 - 2001
  • [5] Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
    Loibl, Sibylle
    Huang, Chiun-Sheng
    Mano, Max S.
    Mamounas, Eleftherios P.
    Geyer, Charles E.
    Untch, Michael
    Thery, Jean-Christophe
    Schwaner, Ingo
    Limentani, Steven
    Loman, Niklas
    Lubbe, Kristina
    Chang, Jenny C.
    Hatschek, Thomas
    Tesarowski, David
    Song, Chunyan
    de Haas, Sanne Lysbet
    Boulet, Thomas
    Lambertini, Chiara
    Wolmark, Norman
    NPJ BREAST CANCER, 2022, 8 (01)
  • [6] Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
    Sibylle Loibl
    Chiun-Sheng Huang
    Max S. Mano
    Eleftherios P. Mamounas
    Charles E. Geyer
    Michael Untch
    Jean-Christophe Thery
    Ingo Schwaner
    Steven Limentani
    Niklas Loman
    Kristina Lübbe
    Jenny C. Chang
    Thomas Hatschek
    David Tesarowski
    Chunyan Song
    Sanne Lysbet de Haas
    Thomas Boulet
    Chiara Lambertini
    Norman Wolmark
    npj Breast Cancer, 8
  • [7] Trastuzumab emtansine for HER2-positive breast cancer
    Venkatesan, Priya
    LANCET ONCOLOGY, 2016, 17 (12): : E528 - E528
  • [8] KATHERINE: Trastuzumab emtansine vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer
    Mamounas, Eleftherios P.
    Geyer, Charles E., Jr.
    Huang, Chiun-Sheng
    Mano, Max S.
    Loibl, Sibylle
    Untch, Michael
    Wolmark, Norman
    Rastogi, Priya
    Schneeweiss, Andreas
    Redondo, Andres
    Fischer, Hans H.
    Jacot, William
    Conlin, Alison K.
    Arce-Salinas, Claudia
    Wapnir, Irene L.
    Jackisch, Christian
    DiGiovanna, Michael P.
    Fasching, Peter A.
    Crown, John P.
    Wuelfing, Pia
    Shao, Zhimin
    Caremoli, Elena Rota
    Wu, Haiyan
    Lam, Lisa H.
    Tesarowski, David
    Smitt, Melanie
    Douthwaite, Hannah
    Singel, Stina M.
    von Minckwitz, Gunter
    SWISS MEDICAL WEEKLY, 2019, 149 : 13S - 13S
  • [9] BUDGET IMPACT ANALYSIS OF TRASTUZUMAB EMTANSINE FOR RESIDUAL INVASIVE HER2-POSITIVE BREAST CANCER IN ARGENTINA
    Penayo, N.
    Peredo, S.
    Olivera, M. S.
    Weissberg, A.
    Tellechea, F.
    Saenz, V
    VALUE IN HEALTH, 2020, 23 : S433 - S433
  • [10] Trastuzumab emtansine: a game changer in HER2-positive early breast cancer
    Mano, Max S.
    FUTURE ONCOLOGY, 2020, 16 (32) : 2595 - 2609
12345